Compare AU
Compare ITEK vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the iShares Future Tech Innovators ETF (ITEK) and the BetaShares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
ITEK | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 2 | 61 |
Median incremental investment | $2,500.00 | $920.50 |
Median investment frequency | Fortnightly | Monthly |
Median total investment | $5,443.13 | $1,892.10 |
Average age group | > 35 | 26 - 35 |
Key Summary
ITEK | DRUG | |
|---|---|---|
Strategy | ITEK.AX was created on 2022-08-15 by iShares. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with the performance of the equally weighted return of the various indices of the Underlying Funds in which the Fund invests, before fees and expenses | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | iShares Elctrc Vhcl&Drvng Tech ETFUSDAcc (17.10 %) iShares Digitalisation ETF USD Acc (17.03 %) iShares Automation&Robotics ETF USD Dist (16.90 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Other (99.97 %) Communication Services (0.00 %) | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) |
Top 3 countries | United States (53.40 %) Japan (7.60 %) China (4.56 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.63 % | 0.57 % |
Key Summary
ITEK | DRUG | |
|---|---|---|
Issuer | iShares | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 0.63 % | 0.57 % |
Price | $29.03 | $7.95 |
Size | $5.923 million | $185.172 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 0.08 % | 1.90 % |
Market | ASX | ASX |
First listed date | 16/08/2022 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
ITEK | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 2 | 61 |
Median incremental investment | $2,500.00 | $920.50 |
Median investment frequency | Fortnightly | Monthly |
Median total investment | $5,443.13 | $1,892.10 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
ITEK | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
ITEK | DRUG |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |